# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and maintains $8 pr...
- SEC Filing
HC Wainwright & Co. analyst Edward White reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Buy and maintains $8 pr...
Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.32) per share which beat the analyst consensus estimate ...
Invited to Present Updated Endometrial Cancer Data During Special Session "ASCO Plenary Series: Rapid Abstract Updates"...
Onco360®, the nation's largest independent Oncology Pharmacy, is now the national specialty pharmacy network partner for Ka...